Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

Keywords

Letrozole, Tamoxifen, Medicine, Aromatase inhibitor, Breast cancer

References

• Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancerMiguel Herrero y Rodríguez de Miñón — 2008
• NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.Robert W. Carlson, Elizabeth Brown, Harold J. Burstein — 2006
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.M Baum, Aman U. Budzar, J Cuzick — 2002
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.NR Williams — 2008
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.The Breast International Group (BIG) 1-98 Collaborative Group — 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.2005
• Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?J. Cuzick, Peter Sasieni, Anthony Howell — 2006
• Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerAnita Giobbie‐Hurder, Karen N. Price, Richard D. Gelber — 2009
• Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategiesJN Ingle, Mitch Dowsett, J Cuzick — 2009
• Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.Manfred Kaufmann, W. Jonat, J. Hilfrich — 2007
• Stopping treatment can reverse acquired resistance to letrozole.Gauri Sabnis, Luciana F. Macedo, Olga Goloubeva — 2008
• Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.L. Mauriac, Aparna Keshaviah, M. Debled — 2006
• A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskMalcolm H. Ray — 1988
• A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*Floyd A. Warren — 2004
• A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.Paul E. Goss, James N. Ingle, Silvana Martino — 2004
• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.R. Jakesz, W. Jonat, Michael Gnant — 2005
• Statistics in medicine--reporting of subgroup analyses in clinical trials.Rui Wang, Stephen W. Lagakos, James H. Ware — 2007
• Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.W. Jonat, Michael Gnant, Francesco Boccardo — 2006
• The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?V. Craig Jordan — 2008
• Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.Rinaa S. Punglia, Karen M. Kuntz, Eric P. Winer — 2005

Cited by

• Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific conceptsMichael Gnant — 2011
• Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trialHani Nassif, Andrzej S. Nowak — 2010
• Neoadjuvant endocrine therapy for breast cancer.Ritika Saini — 2010
• Women and Bone Health: Maximizing the Benefits of Aromatase Inhibitor TherapyShou-Ching Tang — 2010
• Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of ageKristof Van Assche — 2011
• Systemic treatment of early breast cancer—a biological perspectiveShawn M. Carraher, John A. Parnell, Sarah C. Carraher — 2011
• Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum원형식 — 2012
• Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES)Sanaul K. Siddiquee — 2012
• A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.Deirdre Mongan — 2013
• Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivorsMargarita Huesca, Alicia Palacios‐Orueta, J. Litago Lavilla — 2013
• Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.Carolina Sanchís Crespo — 2013
• Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.Irene Crespo — 2014
• Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatmentJennifer S. Holland — 2013
• Estradiol suppresses phosphorylation of ERα serine 167 through upregulation of PP2A in breast cancer cells.Widayati Indarsih, Slamet Suprayogi — 2017
• Regulation of Matrix Metallopeptidase-1 in Breast Cancer MetastasisEric Patrick Henckels — 2013
• Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.Aron Goldhirsch — 2013
• 2012 Nams/Pfizer- Wulf H. Utian Endowed Lecture The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortalityIfeyinwa E. Obiorah, V. Craig Jordan — 2013
• Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208Xiwei Ji, Guangping Chen, Yan Song — 2015
• Expression of CD24 and CD44 in breast cancer cells after cytotoxic drug exposureDaniel Forsman — 2014
• Znaczenie inhibitorów aromatazy w leczeniu chorych na raka piersiTadeusz Pieńkowski — 2012

Related papers

• An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.Jeffrey Tobias, Anthony Howell — 2004
• Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancerMichael Lipsitz, Thomas E. Delea, Amy Guo — 2010
• [Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].Bershteĭn Lm, Danilova Ma, A Iu Kovalevskiĭ — 2009
• PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSISHope S. Rugo, S. Kaura, G Dranitaris — 2009
• A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal womenJuliette Murray, O. E. Young, Lorna Renshaw — 2009
• Anastrozole and letrozole: an investigation and comparison of quality of life and tolerabilityJ. Michael Dixon, Lorna Renshaw, C. Langridge — 2011
• Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.Robert Thomas, Sara Godward, Andreas Makris — 2004
• Drugs in BriefDorothy Bonn — 1997